Johnson & Johnson posts earnings of $1.71 a share vs. $1.68 expected

Wall Street forecast Johnson& Johnson would report quarterly earnings per share of $1.68 on $17.76 billion in revenue, according to consensus estimates from Thomson Reuters. Last month, Johnson& Johnson announced that its schizophrenia treatment, Invega Trinza, was approved by the FDA and commercially available in the U.S. Read More J&J: 10 new drugs by 2019,...